A Multinational, Open-label, Randomised, Controlled Study to Investigate Efficacy and Safety of NNC0365-3769 (Mim8) in Adults and Adolescents With Haemophilia A With or Without Inhibitors
Latest Information Update: 06 Sep 2024
At a glance
- Drugs Mim 8 (Primary)
- Indications Haemophilia A
- Focus Registrational; Therapeutic Use
- Acronyms FRONTIER 2
- Sponsors Novo Nordisk
- 04 Sep 2024 Planned End Date changed from 18 Nov 2024 to 20 Dec 2024.
- 07 Aug 2024 According to a Novo Nordisk media release, Status changed from recruiting to completed.
- 11 Jul 2024 This trial has been completed in Austria, according to European Clinical Trials Database record.